In this large cohort of patients with HCV-related cirrhosis who achieved SVR following DAA therapy, we observed that circulating GPC-3 levels were significantly elevated in patients with HCC and correlated with tumor burden and disease stage. This evidence concerns the gene GPC3 and hepatocellular carcinoma.